28544-30-1Relevant academic research and scientific papers
N-[2-(1 -BENZYLPIPERIDIN-4-YL)ETHYL]-4-(PYRAZIN-2-YL)-PIPERAZINE-1 -CARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS MUSCARINIC RECEPTOR 4 (M4) ANTAGONISTS FOR TREATING NEUROLOGICAL DISEASES
-
Page/Page column 82, (2017/06/22)
Provided herein are small molecule compounds of the following formula (I): or a stereoisomer, tautomer, solvate, ester or pharmaceutically acceptable salt thereof, wherein A, B, C, Li, L 2, Ri, R 2, R 3, R 4, R 5, w, x, y and z are as defined herein. Methods for treating diseases/ disorders by antagonizing muscarinic receptors, including specifically antagonizing muscarinic receptor 4 (M4), are also disclosed. Such diseases/disorders are e.g. neurological diseases/disorders such as e.g. Alzheimer's Disease, Lewy Body Dementia and the cognitive deficits associated with schizophrenia, Parkinson's Disease, drug induced Parkinsonism, dyskinesias, dystonia, chorea, levodopa induced dyskinesia, cerebral palsy, progressive supranuclear palsy, and Huntington's disease. Preferred compounds are e.g. N-[2-(l-benzylpiperidin-4-yl)ethyl]-4- (pyrazin-2-yl)-piperazine-1-carboxamide derivatives and related compounds wherein the pyrazine has been replaced by e.g. pyridazine, pyrimidine, pyridine or phenyl.
Potential psychotropic drugs. X. Synthesis of butyrophenone derivatives with a piperidino spiro tetrahydrooxazinone structure having neuroleptic activity
Bassus,Pacheco,Cier
, p. 416 - 423 (2007/10/05)
New neuroleptic butyrophenone derivations, with a piperidino spirotetrahydrooxa zinone ring have been synthetised. These compounds have a neuroleptic profile analogous to that of haloperidol but their effective doses are higher. They are also less toxic t
